20 completed, 10 recruiting, 2 not yet recruiting, 2 terminated. 39 Phase 3, 5 Phase 2.
Follow Polyradiculoneuropathy: new trials by email Literature Review of Polyradiculoneuropathy trials Research Report on Polyradiculoneuropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Immune globulin (human) 10% solution for intravenous administration - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | Recruiting | Kedrion S.p.A. | 161 | 2026-11-01 | 2026-11-05 |
| A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Empasiprubart IV - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | Phase 2 / Phase 3 | Withdrawn | argenx | 2026-09-01 | 2026-11-13 | |
| A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Gamunex-C, Xembify - CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | Phase 3 | Recruiting | Grifols Therapeutics LLC | 40 | 2026-04-02 | 2026-11-10 |
| A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP Empasiprubart IV, Placebo IV - Chronic Inflammatory Demyelinating Polyneuropathy, CIDP | Phase 3 | Recruiting | argenx | 160 | 2025-09-16 | 2026-11-09 |
| An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) Tanruprubart - Guillain-Barre Syndrome | Phase 3 | Recruiting | Annexon, Inc. | 30 | 2025-09-12 | 2026-10-26 |
| A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP empasiprubart, IVIg, empasiprubart-placebo - Chronic Inflammatory Demyelinating Polyneuropathy, CIDP | Phase 3 | Recruiting | argenx | 218 | 2025-08-22 | 2026-11-03 |
| A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) TAK-881, HYQVIA, SC Investigational Needle Sets - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Phase 3 | Recruiting | Takeda | 59 | 2025-05-06 | 2026-01-20 |
| Efgartigimod for the Treatment of Guillain-Barré Syndrome efgartigimod - Guillain-Barre Syndrome (GBS) | Phase 2 / Phase 3 | Not yet recruiting | Zhongming Qiu | 20 | 2025-04-13 | 2025-03-20 |
| Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP Riliprubart Prefilled Pen (PFP) - Polyneuropathy, Inflammatory Demyelinating, Chronic | Phase 3 | Enrolling by invitation | Sanofi | 300 | 2025-04-01 | 2026-10-27 |
| Ripertamab for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy ripertamab, Placebo - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Phase 3 | Not yet recruiting | Zhongming Qiu | 175 | 2025-03-15 | 2025-03-05 |
| A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) Claseprubart, Placebo - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | Recruiting | Dianthus Therapeutics | 256 | 2025-02-10 | 2026-10-28 |
| Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Rituximab (Mabthera) - CIDP | Phase 3 | Recruiting | Amsterdam University Medical Center (UMC), Location Academic Medical Center (AMC) | 100 | 2024-10-16 | 2024-12-04 |
| A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) riliprubart, Placebo, IVIg - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | Recruiting | Sanofi | 160 | 2024-08-21 | 2026-10-19 |
| A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work Riliprubart, Placebo - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic | Phase 3 | Active not recruiting | Sanofi | 109 | 2024-07-12 | 2026-08-10 |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS) Crovalimab, Placebo, Intravenous immunoglobulin therapy - Guillain-Barré Syndrome | Phase 3 | Withdrawn | Hoffmann-La Roche | 2022-11-30 | 2022-12-15 | |
| Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Nipocalimab, Placebo - Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Phase 2 / Phase 3 | Recruiting | Janssen Research & Development, LLC | 201 | 2022-09-23 | 2026-11-03 |
| A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN) TAK-771 - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Multifocal Motor Neuropathy (MMN) | Phase 3 | Completed | Takeda | 26 | 2022-01-19 | 2026-06-24 |
| IVIG Versus Plasmapheresis in the Treatment of Guillian Barrie Syndrome Patients plasmapheresis device, Intravenous immunoglobulin - Guillain-Barre Syndrome | Phase 2 / Phase 3 | Completed | Assiut University | 81 | 2021-09-01 | 2023-04-06 |
| A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome Eculizumab, Placebo - Guillain-Barre Syndrome | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 57 | 2021-03-08 | 2025-09-08 |
| Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome ANX005, Placebo - Guillain-Barre Syndrome | Phase 3 | Completed | Annexon, Inc. | 242 | 2020-12-17 | 2025-05-29 |
Showing 20 of 39. Sign in to see all of them.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (31) · Guillain-Barre Syndrome (8) · Rare Diseases (5) · Mental Disorders (3) · Neurologic Manifestations (3) · Peripheral Nervous System Diseases (3) · Autoimmune Diseases of the Nervous System (2) · Nervous System Diseases (2) · Autoimmune Diseases (1) · Demyelinating Diseases (1) · Immune System Diseases (1) · Neuromuscular Diseases (1) · Polyneuropathies (1)
Chronic Disease (39) · Disease Attributes (39) · Pathologic Processes (39) · Pathological Conditions, Signs and Symptoms (39) · Autoimmune Diseases (38) · Demyelinating Diseases (38) · Immune System Diseases (38) · Neuromuscular Diseases (38) · Polyneuropathies (38) · Autoimmune Diseases of the Nervous System (37) · Nervous System Diseases (37) · Peripheral Nervous System Diseases (36) · Post-Infectious Disorders (8) · Signs and Symptoms (3)
Immunoglobulins, Intravenous (6) · Immunoglobulins (4) · Hizentra (3) · gamma-Globulins (3) · Rituximab (2) · Solutions (2) · Administration, Intravenous (1) · Albumins (1) · Caprylates (1) · Fingolimod Hydrochloride (1) · Prednisone (1) · Saline Solution (1) · eculizumab (1) · efgartigimod alfa (1)
CSL Behring (3) · National Center for Research Resources (NCRR) (3) · Sanofi (3) · argenx (3) · Annexon, Inc. (2) · Baxalta now part of Shire (2) · Grifols Therapeutics LLC (2) · Laboratoire français de Fractionnement et de Biotechnologies (2) · Nihon Pharmaceutical Co., Ltd (2) · Takeda (2) · Zhongming Qiu (2) · Alexion Pharmaceuticals, Inc. (1) · Amsterdam University Medical Center (UMC), Location Academic Medical Center (AMC) (1) · Assiut University (1) · Centre Hospitalier Universitaire de Saint Etienne (1)
France (17) · Italy (17) · United States (17) · Japan (16) · Spain (15) · Czechia (14) · Germany (14) · Poland (14) · United Kingdom (14) · Canada (12) · Argentina (11) · Denmark (9) · Greece (9) · Netherlands (9) · Turkey (Türkiye) (9)
Anthony J. Windebank (1) · Jerry R. Mendell (1) · Kyoichi Nomura (1) · Lakshmi Deshpande (1) · Norman Latov, MD (1) · Rup Tandan (1) · Wolfgang Frenzel, MD (1)
PMID 42578463, PMID 38353301, PMID 18178525, PMID 19260050, PMID 19365055, PMID 19496683, PMID 20457948, PMID 20647554, PMID 20837852, PMID 23781960, PMID 27455854, PMID 28594116, PMID 28768822, PMID 29122523, PMID 30001923, PMID 38987228, PMID 39523874, PMID 39658326
2023 (3), 2025 (2), 2009 (1), 2014 (1), 2016 (1)